Spots Global Cancer Trial Database for Phase II CT-2103/Carboplatin in Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II CT-2103/Carboplatin in Ovarian Cancer
Official Title: CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study
Study ID: NCT00069901
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Detailed Description: CT-2103 is a pharmaceutical that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer. The objective of this trial is to evaluate the toxicity, estimate the response rate, progression-free survival and overall survival in patients with newly diagnosed stage III or IV ovarian or primary peritoneal carcinoma treated with CT-2103 in combination with carboplatin.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
California Cancer Care, Greenbrae, California, United States
Gynecology Oncology Associates, Greenbrae, California, United States
Stockton Hematology Oncology Medical, Stockton, California, United States
Raben and Fldman Research Associates, South Miami, Florida, United States
University of Louisville, Louisville, Kentucky, United States
Resource Center for Gynecology/ Oncology, Kansas City, Missouri, United States
Upstate New York Cancer Research and Education Foundation, Rochester, New York, United States
Gynecology, Oncology, and Pelvic Surgery Associates, Inc., Columbus, Ohio, United States
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
Guthrie Foundation for Education and Research, Sayre, Pennsylvania, United States
South Carolina Oncology Assoicates, Columbia, South Carolina, United States
Chattanooga GYN-Oncology, Chattanooga, Tennessee, United States
Baptist Regional Cancer Center, Knoxville, Tennessee, United States
Arlington Fairfax Hematology Oncology, Arlington, Virginia, United States
Pacific Gynecology Specialists, Seattle, Washington, United States
Swedish Cancer Institute, Seattle, Washington, United States
Aurora Health Care, Inc., Milwaukee, Wisconsin, United States
Contact Details
Name: Scott Stromatt, M.D.
Affiliation: CTI BioPharma
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
